Bioqube Ventures is a global life sciences venture capital firm with offices in Belgium and the United States, investing in companies developing first- or best-in-class therapeutics from inception through early clinical milestones.
50% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Average disclosed round size is $88.4M (across 8 rounds with reported amounts).
Portfolio
15
Fund Size
$66M
Top Stage
Seed
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| PPrimmune Therapeutics | Series B | $23.3M | Jan 2026 |
 Actithera | Series A | $75.5M | Jul 2025 |
 Spica Therapeutics | Seed | — | Jun 2025 |
 Commit Biologics | Seed | — | Jan 2025 |
| SSynox Therapeutics | Pre-Seed | $92M | Oct 2024 |
 Catalym | Series D | $150M | Jul 2024 |
| Commit Biologics | Seed | — | May 2024 |
| SSynox Therapeutics | Series B | $75M | Apr 2024 |
 Anavo Therapeutics | Seed | — | May 2023 |
| AAnavo | Seed | — | May 2023 |
 Tridek One | Series A | — | Sep 2022 |
| TTridek-One | Unknown | — | Sep 2022 |
 Egle Therapeutics | Series A | — | Oct 2021 |
| EEnhanc3D Genomics | Seed | — | Jan 2021 |
| TTridek-One | Unknown | — | Jan 2019 |
| Actithera | Series A | $75.5M | — |
| SSpica | Seed | — | — |
| EEnhanc3D Genomics | Series A | — | — |
 Bicara Therapeutics | Series B | $108M | — |
| BBicara | Series B | $108M | — |
Top Co-Investors
Bpifrance4 shared
M Ventures4 shared
AdBio partners3 shared
Pureos Bioventures3 shared
Gilde Healthcare3 shared
Omega Funds3 shared
EQT Life Sciences2 shared
4BIO Capital2 shared
Investinor2 shared
Sofinnova Partners2 shared
Surveyor Capital2 shared
Hadean Ventures2 shared
MRL Ventures Fund2 shared
Merck2 shared
INKEF Capital2 shared
Hercules Capital, Inc.2 shared
Forbion2 shared
HealthCap2 shared
Novo Capital2 shared
Novo Holdings A/S2 shared
Last updated: 20 October 2026